These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 26213107)

  • 1. CD70: An emerging target in cancer immunotherapy.
    Jacobs J; Deschoolmeester V; Zwaenepoel K; Rolfo C; Silence K; Rottey S; Lardon F; Smits E; Pauwels P
    Pharmacol Ther; 2015 Nov; 155():1-10. PubMed ID: 26213107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targeting of CD70 and CD27.
    Wajant H
    Expert Opin Ther Targets; 2016 Aug; 20(8):959-73. PubMed ID: 26914723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer.
    Jacobs J; Zwaenepoel K; Rolfo C; Van den Bossche J; Deben C; Silence K; Hermans C; Smits E; Van Schil P; Lardon F; Deschoolmeester V; Pauwels P
    Oncotarget; 2015 May; 6(15):13462-75. PubMed ID: 25951351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma.
    Miller J; Eisele G; Tabatabai G; Aulwurm S; von Kürthy G; Stitz L; Roth P; Weller M
    J Neurosurg; 2010 Aug; 113(2):280-5. PubMed ID: 19961309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology.
    Nolte MA; van Olffen RW; van Gisbergen KP; van Lier RA
    Immunol Rev; 2009 May; 229(1):216-31. PubMed ID: 19426224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential.
    van de Ven K; Borst J
    Immunotherapy; 2015; 7(6):655-67. PubMed ID: 26098609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD70 as a therapeutic target in human malignancies.
    Grewal IS
    Expert Opin Ther Targets; 2008 Mar; 12(3):341-51. PubMed ID: 18269343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CD70 for human therapeutic use.
    Boursalian TE; McEarchern JA; Law CL; Grewal IS
    Adv Exp Med Biol; 2009; 647():108-19. PubMed ID: 19760069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27.
    Yoshino K; Kishibe K; Nagato T; Ueda S; Komabayashi Y; Takahara M; Harabuchi Y
    Br J Haematol; 2013 Feb; 160(3):331-42. PubMed ID: 23206232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo.
    Aulwurm S; Wischhusen J; Friese M; Borst J; Weller M
    Int J Cancer; 2006 Apr; 118(7):1728-35. PubMed ID: 16217761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal stimulation for CD70 induction on human monocyte-derived dendritic cells and the importance of CD70 in naive CD4(+) T-cell differentiation.
    Arimoto-Miyamoto K; Kadowaki N; Kitawaki T; Iwata S; Morimoto C; Uchiyama T
    Immunology; 2010 May; 130(1):137-49. PubMed ID: 20201989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of CD70-CD27 interaction inhibits induction of allergic lung inflammation in mice.
    Makino F; Ito J; Abe Y; Harada N; Kamachi F; Yagita H; Takahashi K; Okumura K; Akiba H
    Am J Respir Cell Mol Biol; 2012 Sep; 47(3):298-305. PubMed ID: 22499851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8+ T cells produce the chemokine CXCL10 in response to CD27/CD70 costimulation to promote generation of the CD8+ effector T cell pool.
    Peperzak V; Veraar EA; Xiao Y; Babala N; Thiadens K; Brugmans M; Borst J
    J Immunol; 2013 Sep; 191(6):3025-36. PubMed ID: 23940275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens.
    Zeng W; Su M; Anderson KS; Sasada T
    Immunobiology; 2014 Aug; 219(8):583-92. PubMed ID: 24713579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity.
    Keller AM; Schildknecht A; Xiao Y; van den Broek M; Borst J
    Immunity; 2008 Dec; 29(6):934-46. PubMed ID: 19062317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. γδ T cells develop, respond and survive - with a little help from CD27.
    Born WK; O'Brien RL
    Eur J Immunol; 2011 Jan; 41(1):26-8. PubMed ID: 21182073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity.
    Cormary C; Hiver E; Mariamé B; Favre G; Tilkin-Mariamé AF
    Cancer Gene Ther; 2005 Dec; 12(12):963-72. PubMed ID: 15956983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct cellular communications between CD45R0 and CD45RA T cell subsets via CD27/CD70.
    Agematsu K; Kobata T; Sugita K; Hirose T; Schlossman SF; Morimoto C
    J Immunol; 1995 Apr; 154(8):3627-35. PubMed ID: 7706706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7).
    Starzer AM; Berghoff AS
    ESMO Open; 2020 Mar; 4(Suppl 3):e000629. PubMed ID: 32152062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD27/CD70 interaction directly drives B cell IgG and IgM synthesis.
    Agematsu K; Kobata T; Yang FC; Nakazawa T; Fukushima K; Kitahara M; Mori T; Sugita K; Morimoto C; Komiyama A
    Eur J Immunol; 1995 Oct; 25(10):2825-9. PubMed ID: 7589078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.